Table 1.
Clinical characteristics of patients with HCC in the overall study cohort.
| Characteristic | N = 184 | N (%) or median (range) |
|---|---|---|
| Gender | Female vs. male | 34 (18.5%) vs. 150 (81.5%) |
| Age (y) | 58 (22–87) | |
| KPS | ≥90 vs. <90 | 168 (91.3%) vs. 16 (8.7%) |
| Child-Pugh | 5 vs. 6 vs. ≥7 | 76 (41.3%) vs. 70 (38.0%) vs.28 (15.3%) |
| Unknown | 10 (5.4%) | |
| BCLC stage | A vs. B vs. C | 57 (31%) vs. 71 (38.6%) vs. 50 (27.2%) |
| Unknown | 6 (3.3%) | |
| HBV | Negative vs. positive | 47 (25.5%) vs. 137 (74.5%) |
| AFP (UI/ml) | 28.1 (0–60500) | |
| Tumor thrombus | Yes vs. no | 32 (17.4%) vs. 152 (82.6%) |
| LNM | Yes vs. no | 22 (12.0%) vs. 162 (88.0%) |
| TACE | Yes vs. no | 109 (59.2%) vs. 75 (40.8%) |
| RFA | Yes vs. no | 18 (9.8%) vs. 166 (90.2%) |
| Tumor size (cm) | 4.1 (0.7–24.0) | |
| ALC pre-RT (×109/L) | 1.3 (0.2–3.5) | |
| ALC post-RT (×109/L) | 0.5 (0.1–2.2) | |
| Lymphocyte nadir (×109/L) | 0.5 (0.1–2.6) | |
| WBC nadir (×109/L) | 3.7 (1.5–13.4) | |
| Mono nadir (×109/L) | 0.3 (0.1–1.1) | |
| Neut nadir (×109/L) | 2.5 (0.7–12.2) | |
| RT fractionation | CFRT vs. HFRT vs. SBRT | 53 (37.0%) vs. 58 (31.5%) vs. 73 (31.5%) |
| BED (Gy) | 75.0 (50.0–119.0) | |
| Fractions | 16 (5–35) | |
| GTV (cc) | 55.0 (1.6–1880.1) |
KPS = Karnofsky Performance Status; BCLC stage = Barcelona Clinic Liver Cancer stage; HBV = hepatitis B virus; AFP = alpha-fetoprotein; LNM = lymph node metastasis; TACE = transcatheter arterial chemoembolization; RFA = radiofrequency ablation; ALC = absolute lymphocyte count; ALC pre-RT = ALC within two weeks before the start of RT; ALC post-RT = ALC within 1 week after the end of RT; ALC post-pre = ALC at post-RT minus ALC at pre-RT; WBC = white blood cell; Mono = monocyte; Neut = neutrophil; RT = radiotherapy; BED = biologically effective dose; and GTV = gross target volume.